Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision to set up its own oncology team to commercialize Somatuline Depot (lanreotide) in neuroendocrine tumors (NETs) in the USA. 22 January 2014
Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its CNS Drug Discovery Unit, Pharmaceutical Research Division. 15 January 2014
US generics and specialty drugmaker Actavis has announced an updated business structure for its US Specialty Brands business designed to maximize the company's newly-strengthened position in key therapeutic areas and position it for continued long-term growth. 14 January 2014
Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology, will leave the company with immediate effect having decided to “pursue a career opportunity outside of the organization.” 13 January 2014
German privately-owned pharma company Priaxon AG has appointed Constance Hoefer as chief development officer (CDO) to oversee non-clinical and early clinical development. 9 January 2014
Somewhat sooner than expected, Isael’s Teva Pharmaceutical Industries, the world’s largest generics drugmaker, has confirmed recent reports, saying that Erez Vigodman has been appointed president and chief executive, effective February 11. 9 January 2014
Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), has named Steven Hildemann as global chief medical officer and head of global medical and safety for the Merck Serono division. 9 January 2014
US biotech company Promedior has announced that industry veteran William Hodder has joined the company as Vice President of Business Development. 8 January 2014
US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard Wooster as chief scientific officer. 7 January 2014
Speculation is mounting that Israel’s Teva Pharmaceutical Industries is about to appoint a new chief executive, after ousting 18-month incumbent of the post, Jeremy Levin, last October. 7 January 2014
US drugmaker Mylan says that Rakesh Bamzai has joined the company and has been appointed president, India commercial and emerging markets. 4 January 2014
US synthetic biology companies Agilis Biotherapeutics and Intrexon have entered an exclusive channel collaboration to develop DNA-based therapeutics for Friedreich's ataxia, a rare genetic neurodegenerative disease. 1 January 2014
The supervisory board of German drugs and chemicals major Bayer (BAYN: DE) has appointed Kemal Malik to the Board of Management with the responsibility for innovation and taking over the North America region. 20 December 2013
French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice President in charge of Human Resources of the Ipsen group in place of Etienne de Blois. 19 December 2013